The Latest Breaking News from CSL

KOCHI 

Haemonetics Corporation's (NYSE: HAE) analyst day later this month may include an update on its businesses, new products, margin outlook, and financial targets for FY24-FY26.

HC Wainwright has removed Angion Biomedica Corp's (NASDAQ:ANGN) former lead candidate, ANG-3777, in acute kidney injury (AKI), from its valuation assessment. The analyst has reduced the price target from $50 to $32, with a Buy rating. In the Q4 earnings release, the Company decided to discontinue the development of ANG-3777 after disappointing data. The analyst…

Paul Bennetts was a successful businessman and NHS manager but now he is facing months behind bars

Shipyard inks pact with Dredging Corporation of India to build the 127-metre-long, 28-metre-wide vessel

An apparent easing in European geopolitical tensions supported US equity markets during the first half of the week. Here's a wrap of this week in markets.

Blood products giant CSL says that its ability to collect plasma has been improving as social mobility increases.

The Australian share market rises in afternoon trade, soaring oil and gas prices boost Santos' profit, while Fortescue Metals, CSL and Treasury Wine Estates reveal the impact of COVID-19 on their earnings.

Pact envisages mutual support in R&D among other areas